CA2435551A1 - Families of non-cross-hybridizing polynucleotides for use as tags and tag complements, manufacture and use thereof - Google Patents
Families of non-cross-hybridizing polynucleotides for use as tags and tag complements, manufacture and use thereof Download PDFInfo
- Publication number
- CA2435551A1 CA2435551A1 CA002435551A CA2435551A CA2435551A1 CA 2435551 A1 CA2435551 A1 CA 2435551A1 CA 002435551 A CA002435551 A CA 002435551A CA 2435551 A CA2435551 A CA 2435551A CA 2435551 A1 CA2435551 A1 CA 2435551A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- composition
- molecules
- hundred
- alignment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B20/00—Methods specially adapted for identifying library members
- C40B20/04—Identifying library members by means of a tag, label, or other readable or detectable entity associated with the library members, e.g. decoding processes
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Abstract
A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 1168 24mers is described.
Claims (95)
1. A composition comprising molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a following group of sequences,
2 3 1 2 3 2 2 1 3 1 1 3 2 1 2 1 2 2 3 2 3 1 1 2
3 2 3 2 2 2 1 2 3 2 2 1 2 1 2 3 2 3 1 1 3 2 2 2 2 3 2 3 1 3 1 1 2 2 1 1 3 1 2 2 1 1 3 l 1 2 3 2 1 1.1 3 1 2 3 1 2 2 3 2 1 1 2 2 2 3 2 3 2 3 1 1 3 1 2 2 1 3 2 1 2 2 2 1 3 2 1 3 2 1 1 2 1 3 1 3.
2 1 2 2 2 3 2 3 2.2 2 3 2 2 3 1 2 2 1 3 1 2 1 3 1 1 2 1 1 1 3 2 2~ 1 2 2 3 1 3 1 3 1 3 2 2 2 1 3 wherein each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:
for any pair of sequences of the set:
M1 <= 15, M2 <= 12, M3 <= 19, M4 <= 15, and M5 <= 18, where:
M1 is the maximum number of matches for any allignment in which there are no internal indels;
M2 is the maximum length of a block of matches for any allignment;
M3 is the maximum number of matches for any alignment having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score;
wherein:
the score of an alignment is determined according to the equation (A
x m) - (B x mm) - (C x (og + eg)) - (D x eg)), wherein:
for each of (i) to (iv):
(i) m = 6, mm = 6, og = 0 and eg = 6, (ii) m= 6, mm = 6, og = 5 and eg = 1, (iii) m = 6, mm = 2, og = 5 and eg = 1, and (iv) m = 6, mm = 6, og = 6 and eg = 0, A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and wherein the maximum score is determined separately for each of (i), (ii), (iii) and (iv).
2. A composition comprising molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a group of sequences having the numeric pattern of sequences set out in claim 1, wherein each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:
for any pair of sequences of the set:
M1 <= 18, M2 <= 16, M3 <= 20, M4 <= 17, and M5 <= 19, where:
M1 is the maximum number of matches for any alignment in which there are no internal indels;
M2 is the maximum length of a block of matches for any alignment;
M3 is the maximum number of matches for any alignment having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score;
wherein the score of an alignment is determined according to the equation (A
x m) - (B x mm) - (C x (og + eg)) - (D x eg)), wherein:
for each of (i) to (iv):
(i) m = 6, mm = 6, og = 0 and eg = 6, (ii) m = 6, mm = 6, og = 5 and eg = 1, (iii) m = 6, mm = 2, og = 5 and eg = 1, and (iv) m = 6, mm = 6, og = 6 and eg = 0, A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and wherein the maximum score is determined separately for each of (i), (ii) , (iii) and (iv).
3. A composition comprising molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a group of sequences having the numeric patterns set out in claim 1, wherein each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:
for any pair of sequences of the set:
M1 <= 18, M2 <= 16, M3 <= 20, M4 <= 17, and M5 <= 19, where:
M1 is the maximum number of matches for any alignment in which there are no internal indels;
M2 is the maximum length of a block of matches for any alignment;
M3 is the maximum number of matches for any alignment having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score, wherein:
the score of an alignment is determined according to the equation 3A
- B - 3C - D, wherein:
A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and
2 1 2 2 2 3 2 3 2.2 2 3 2 2 3 1 2 2 1 3 1 2 1 3 1 1 2 1 1 1 3 2 2~ 1 2 2 3 1 3 1 3 1 3 2 2 2 1 3 wherein each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:
for any pair of sequences of the set:
M1 <= 15, M2 <= 12, M3 <= 19, M4 <= 15, and M5 <= 18, where:
M1 is the maximum number of matches for any allignment in which there are no internal indels;
M2 is the maximum length of a block of matches for any allignment;
M3 is the maximum number of matches for any alignment having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score;
wherein:
the score of an alignment is determined according to the equation (A
x m) - (B x mm) - (C x (og + eg)) - (D x eg)), wherein:
for each of (i) to (iv):
(i) m = 6, mm = 6, og = 0 and eg = 6, (ii) m= 6, mm = 6, og = 5 and eg = 1, (iii) m = 6, mm = 2, og = 5 and eg = 1, and (iv) m = 6, mm = 6, og = 6 and eg = 0, A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and wherein the maximum score is determined separately for each of (i), (ii), (iii) and (iv).
2. A composition comprising molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a group of sequences having the numeric pattern of sequences set out in claim 1, wherein each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:
for any pair of sequences of the set:
M1 <= 18, M2 <= 16, M3 <= 20, M4 <= 17, and M5 <= 19, where:
M1 is the maximum number of matches for any alignment in which there are no internal indels;
M2 is the maximum length of a block of matches for any alignment;
M3 is the maximum number of matches for any alignment having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score;
wherein the score of an alignment is determined according to the equation (A
x m) - (B x mm) - (C x (og + eg)) - (D x eg)), wherein:
for each of (i) to (iv):
(i) m = 6, mm = 6, og = 0 and eg = 6, (ii) m = 6, mm = 6, og = 5 and eg = 1, (iii) m = 6, mm = 2, og = 5 and eg = 1, and (iv) m = 6, mm = 6, og = 6 and eg = 0, A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and wherein the maximum score is determined separately for each of (i), (ii) , (iii) and (iv).
3. A composition comprising molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide selected from a set of oligonucleotides based on a group of sequences having the numeric patterns set out in claim 1, wherein each of 1 to 3 is a nucleotide base selected to be different from the others of 1 to 3 with the proviso that up to three nucleotide bases of each sequence can be substituted with any nucleotide base provided that:
for any pair of sequences of the set:
M1 <= 18, M2 <= 16, M3 <= 20, M4 <= 17, and M5 <= 19, where:
M1 is the maximum number of matches for any alignment in which there are no internal indels;
M2 is the maximum length of a block of matches for any alignment;
M3 is the maximum number of matches for any alignment having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of maximum score; and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of maximum score, wherein:
the score of an alignment is determined according to the equation 3A
- B - 3C - D, wherein:
A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and
4. A composition according to any preceding claim, wherein for the group of 24mer sequences in which 1 = A, 2 = T and 3 = G, under a defined set of conditions in which the maximum degree of hybridization between a sequence and any complement of a different sequence of the group of 24mer sequences does not exceed 30% of the degree of hybridization between said sequence and its complement, for all said oligonucleotides of the composition, the maximum degree of hybridization between an oligonucleotide and a complement of any other oligonucleotide of the composition does not exceed 50% of the degree of hybridization of the oligonucleotide and its complement.
5. The composition of claim 4, wherein said maximum degree of hybridization between a sequence and any complement of a different sequence does not exceed 30% of the degree of hybridization between said sequence and its complement, the degree of hybridization between each sequence and its complement varies by a factor of between 1 and up to 10, more preferably between 1 and up to 9, more preferably between 1 and up to 8, more preferably between 1 and up to 7, more preferably between 1 and up to 6, and more preferably between 1 and up to 5.
6. The composition of claim 4 or 5, wherein the maximum degree of hybridization between a sequence and any complement of a different sequence does not exceed 25%, more preferably does not exceed 20%, more preferably does not exceed 15%, more preferably does not exceed 10%, more preferably does not exceed 5%.
7. The composition of any of claims 4 to 6, wherein said defined set of conditions results in a level of hybridization that is the same as the level of hybridization obtained when hybridization conditions include 0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0 at 37°C.
8. The composition of any of claims 4 to 7, said defined set of conditions includes the group of 24mer sequences being covalently linked to beads.
9. The composition of claim 4 wherein, for the group of 24mers the maximum degree of hybridization between a sequence and any complement of a different sequence does not exceed 15% of the degree of hybridization between said sequence and its complement and the degree of hybridization between each sequence and its complement varies by a factor of between 1 and up to 9, and for.all oligonucleotides of the set, the maximum degree of hybridization between an oligonucleotide and a complement of any other oligonucleotide of the set does not exceed 20% of the degree of hybridization of the oligonucleotide and its complement.
10. The composition of any preceding claim wherein: each 1 is one of A, T/U, G and C; each 2 is one of A, T/U, G and C; and each 3 is one of A, T/U, G and C; and each of 1, 2 and 3 is selected so as to be different from all of the others of 1, 2 and 3.
11. The composition of claim 10, wherein 1 is A or T/U, 2 is A or T/U
and 3 is G or C.
and 3 is G or C.
12. The composition of claim 11, wherein 1 is A, 2 is T/U and 3 is G.
13. The composition of any preceding claim, wherein each said oligonucleotide is from twenty-two to twenty-six bases in length, or from twenty-three to twenty-five.
14. The composition of any of claims 1 to 13, wherein each said oligonucleotide is of the same length as every other said oligonucleotide.
15. The composition of claim 14, wherein each said oligonucleotide is twenty-four bases in length.
16. The composition of any of claims 1 to 13 wherein no said oligonucleotide contains more than four contiguous bases that are identical to each other.
17. The composition of any of claims 1 to 12 and 16 wherein the number of G's in each said oligonucleotide does not exceed L/4 where L is the number of bases in said sequence.
18. The composition of any of claims 1 to 24 and 16 and 17, wherein the number of G's in each said oligonucleotide does not vary from the average number of G's in all of the said oligonucleotides by more than one.
19. The composition of any claims 1 to 14 and 16 to 18, wherein the number of G's in each said oligonucleotide is the same as every other said oligonucleotide.
20. The composition of claim 19, wherein each said oligonucleotide is twenty-four bases in length and each said oligonucleotide contains 6 G's.
21. The composition of any of claims 1 to 12 and claims 16 to 20, wherein, for each said nucleotide, there is at most six bases other than G between every pair of neighboring pairs of G's.
22. The composition of any of claims 1 to 12 and claims 16 to 21, wherein at the 5'-end of each said oligonucleotide at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence of the oligonculeotide is a G.
23. The composition of any of claims 1 to 12 and claims 16 to 21, wherein at the 3'-end of each said oligonucleotide at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence of the oligonucleotide is a G.
24. The composition of claim 22, wherein at the 3'-end of each said oligonucleotide at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence of the oligonucleotide is a G.
25. The composition of any of claims 1 to 24, comprising ten, or twenty, or thirty, or forty, or fifty, or sixty, or seventy, or eighty, or ninety, or one hundred, or one hundred and ten, or one hundred and twenty, or one hundred and thirty, or one hundred and forty, or one hundred and fity, or one hundred and sixty said molecules, or comprising one hundred and seventy said molecules, or comprising one hundred and eighty said molecules, or comprising one hundred and ninety said molecules, or comprising two hundred said molecules, or comprising two hundred and twenty said molecules, or comprising two hundred. and forty said molecules, or comprising two hundred and sixty said molecules, or comprising two hundred and eighty said molecules, or comprising three hundred said molecules, or comprising four hundred said molecules, or comprising five hundred said molecules, or comprising six hundred said molecules, or comprising seven hundred said molecules, or comprising eight hundred said molecules, or comprising nine hundred said molecules, or comprising one thousand said molecules, eleven hundred said molecules.
26. A composition of any of claims 1 to 25, wherein each said molecule is linked to a solid phase support so as to be distinguishable from a mixture of other said molecules by hybridization to its complement.
27. The composition of claim 26, wherein each molecule is linked to a defined location on a said solid phase support, the defined location for each said molecule being different than the defined location for different other said molecules.
28. The composition of claim 27, wherein each said solid phase support is a microparticle and each said molecule is covalently linked to a different microparticle than each other different said molecule.
29. A composition comprising a set of 150 molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide having a sequence of at least sixteen nucleotide bases wherein for any pair of sequences of the set:
M1 > 19/24 x L1, M2 > 17/24 x L1, M3 > 21/24 x L1, M4 > 18/24 x L1, M5 >
20/24 x L1, where L1 is the length of the shortest sequence of the pair, where:
M1 is the maximum number of matches for any alignment of the pair of sequences in which there are no internal indels;
M2 is the maximum length of a block of matches for any alignment of the pair of sequences;
M3 is the maximum number of matches for any alignment of the pair of sequences having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of the pair of sequences of maximum score;
and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of the pair of sequences of maximum score, wherein:
the score of an alignment is determined according to the equation (A
x m) - (B x mm) - (C x (og + eg)) - (D x eg)), wherein:
for each of (i) to (iv) (i) m = 6, mm = 6, og = 0 and eg = 6, (ii) m = 6, mm = 6, og = 5 and eg = 1, (iii) m = 6, mm = 2, og = 5 and eg = 1, and (iv) m = 6, mm = 6, og = 6 and eg = 0, A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and wherein the maximum score is determined separately for each of (i), (ii), (iii) and (iv).
M1 > 19/24 x L1, M2 > 17/24 x L1, M3 > 21/24 x L1, M4 > 18/24 x L1, M5 >
20/24 x L1, where L1 is the length of the shortest sequence of the pair, where:
M1 is the maximum number of matches for any alignment of the pair of sequences in which there are no internal indels;
M2 is the maximum length of a block of matches for any alignment of the pair of sequences;
M3 is the maximum number of matches for any alignment of the pair of sequences having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of the pair of sequences of maximum score;
and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of the pair of sequences of maximum score, wherein:
the score of an alignment is determined according to the equation (A
x m) - (B x mm) - (C x (og + eg)) - (D x eg)), wherein:
for each of (i) to (iv) (i) m = 6, mm = 6, og = 0 and eg = 6, (ii) m = 6, mm = 6, og = 5 and eg = 1, (iii) m = 6, mm = 2, og = 5 and eg = 1, and (iv) m = 6, mm = 6, og = 6 and eg = 0, A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment; and wherein the maximum score is determined separately for each of (i), (ii), (iii) and (iv).
30. A composition comprising a set of 150 molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide having a sequence of at least sixteen nucleotide bases wherein for any pair of sequences of the set:
M1 <= 18, M2 <= 16, M3 <= 20, M4 <= 17, and M5 <= 19, where:
M1 is the maximum number of matches for any alignment of the pair of sequences in which there are no internal indels;
M2 is the maximum length of a block of matches for any alignment of the pair of sequences;
M3 is the maximum number of matches for any alignment of the pair of sequences having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of the pair of sequences of maximum score;
and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of the pair of sequences of maximum score, wherein:
the score of a said alignment is determined according to the equation 3A - B - 3C - D, wherein:
A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment.
M1 <= 18, M2 <= 16, M3 <= 20, M4 <= 17, and M5 <= 19, where:
M1 is the maximum number of matches for any alignment of the pair of sequences in which there are no internal indels;
M2 is the maximum length of a block of matches for any alignment of the pair of sequences;
M3 is the maximum number of matches for any alignment of the pair of sequences having a maximum score;
M4 is the maximum sum of the lengths of the longest two blocks of matches for any alignment of the pair of sequences of maximum score;
and M5 is the maximum sum of the lengths of all the blocks of matches having a length of at least 3, for any alignment of the pair of sequences of maximum score, wherein:
the score of a said alignment is determined according to the equation 3A - B - 3C - D, wherein:
A is the total number of matched pairs of bases in the alignment;
B is the total number of internal mismatched pairs in the alignment;
C is the total number of internal gaps in the alignment; and D is the total number of internal indels in the alignment minus the total number of internal gaps in the alignment.
31. The composition of claim 29 or 30, wherein each said sequence has up to fifty bases.
32. The composition of claim 31, wherein each said sequence is between sixteen and forty bases in length, or between sixteen and thirty-five bases in length, or between eighteen and thirty bases in length, or between twenty and twenty-eight bases in length, or between twenty-one and twenty-seven bases in length, or between twenty-two and twenty-six bases in length.
33. The composition of any of claims 29 to 32, wherein each said sequence is of the same length as every other said sequence.
34. The composition of claim 33, wherein each said sequence is twenty-four bases in length.
35. The composition of any of claims 29 to 34 wherein no said sequence contains more than four contiguous bases that are identical to each other.
36. The composition of any of claims 29 to 35 wherein the number of G's in each said sequence does not exceed L/4 where L is the number of bases in said sequence.
37. The composition of claim 36, wherein the number of G's in each said sequence does not vary from the average number of G's in all of the sequences of the set by more than one.
38. The composition of claim 37, wherein the number of G's in each said sequence is the same as every other sequence of the set.
39. The composition of claim 37, wherein each said sequence is twenty-four bases in length and each said sequence contains 6 G's.
40. The composition of any of claims 29 to 39 wherein, for each said sequence, there is at most six bases other than G between every pair of neighboring pairs of G's.
41. The composition of any of claims 29 to 40, wherein at the 5'-end of each said sequence at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence is a G.
42. The composition of any of claims 29 to 40, wherein at the 3'-end of each said sequence at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence is a G.
43. The composition of claim 41, wherein at the 3'-end of each said sequence at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence is a G.
44. The composition of any of claims 29 to 43, wherein under a defined set of conditions, the maximum degree of hybridization between a said oligonucleotide and any complement of a different oligonucleotide of the composition does not exceed about 30% of the degree of hybridization between said oligonucleotide and its complement, more preferably 20%, more preferably 15%, more preferably 10%, more preferably 6%.
45. The composition of clam 44, wherein said set of conditions results in a level of hybridization that is the same as the level of hybridization obtained when hybridization conditions include 0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0 at 37°C, and the oligonucleotides are covalently linked to microparticles.
46. The composition of claim 45, wherein under said defined set of conditions, the degree of hybridization between each oligonucleotide and its complement varies by a factor of between 1 and up to 8, more preferably up to 7, more preferably up to 6, more preferably.up to 5.
47. The composition of any of claims 29 to 46, comprising one hundred and sixty said molecules, or comprising one hundred and seventy said molecules, or comprising one hundred and eighty said molecules, or comprising one hundred and ninety said molecules, or comprising two hundred said molecules, or comprising two hundred and twenty said molecules, or comprising two hundred and forty said molecules, or comprising two hundred and sixty said molecules, or comprising two hundred and eighty said molecules, or comprising three hundred said molecules, or comprising four hundred said molecules, or comprising five hundred said molecules, or comprising six hundred said molecules, or comprising seven hundred said molecules, or comprising eight hundred said molecules, or comprising nine hundred said molecules, or comprising one thousand said molecules.
48. A composition of any of claims 29 to 47, wherein each said molecule is linked to a solid phase support so as to be distinguishable from a mixture of other said molecules by hybridization to its complement.
49. The composition of claim 48, wherein each molecule is linked to a defined location on a said solid phase support, the defined location for each said molecule being different than the defined location for different other said molecules.
50. The composition of claim 49, wherein each said solid phase support is a microparticle and each said molecule is covalently to a different microparticle than each other different said molecule.
51. A composition comprising one hundred and fifty minimally cross-hybridizing molecules for use as tags or tag complements wherein each molecule comprises an oligonucleotide comprising a sequence of nucleotide bases for which, under a defined set of conditions, the maximum degree of hybridization between a said oligonucleotide and any complement of a different oligonucleotide does not exceed about 20% of the degree of hybridization between said oligonucleotide and its complement.
52. The composition of claim 51, wherein each said sequence has between ten and fifty bases.
53. The composition of claim 52, wherein each said sequence is between sixteen and forty bases in length, or between sixteen and thirty-five bases in length, or between eighteen and thirty bases in length, or between twenty and twenty-eight bases in length, or between twenty-one and twenty-seven bases in length, or between twenty-two and twenty-six bases in length.
54. The composition of any of claims 51 to 53, wherein each said sequence is of the same length as every other said sequence.
55. The composition of claim 54, wherein each said sequence is twenty-four bases in length.
56. The composition of any of claims 51 to 55 wherein no said sequence contains more than four contiguous bases that are identical to each other.
57. The composition of any of claims 51 to 56 wherein the number of G's in each said sequence does not exceed L/4 where L is the number of bases in said sequence.
58. The composition of claim 57, wherein the number of G's in each said sequence does not vary from the average number of G's in all of the sequences of the set by more than one.
59. The composition of claim 58, wherein the number of G's in each said sequence is the same as every other sequence of the set.
60. The composition of claim 58, wherein each said sequence is twenty-four bases in length and each said sequence contains 6 G's.
61. The composition of any of claims 51 to 60 wherein, for each said sequence, there is at most six bases other than G between every pair of neighboring pairs of G's.
62. The composition of any of claims 51 to 61, wherein at the 5'-end of each said sequence at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence is a G.
63. The composition of any of claims 51 to 61, wherein at the 3'-end of each said sequence at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence is a G.
64. The composition of claim 62, wherein at the 3'-end of each said sequence at least one of the first, second, third, fourth, fifth, sixth and seventh bases of the sequence is a G.
65. The composition of any of claims 61 to 64, wherein under a said defined set of conditions, the maximum degree of hybridization between a said oligonucleotide and any complement of a different oligonucleotide of the composition does not exceed about 15%, more preferably 10%, more preferably 6%.
66. The composition of claim 65, wherein said set of conditions results in a level of hybridization that is the same as the level of hybridization obtained when hybridization conditions include 0.2 M NaCl, 0.1 M Tris, 0.08% Triton X-100, pH 8.0 at 37°C, and the oligonucleotides are covalently linked to microparticles.
67. The composition of claim 66, wherein under said defined set of conditions, the degree of hybridization between each oligonucleotide and its complement varies by a factor of between 1 and up to 8, more preferably up to 7, more preferably up to 6, more preferably up to 5.
68. The composition of any of claims 51 to 67, comprising one hundred and sixty said molecules, or comprising one hundred and seventy said molecules, or comprising one hundred and eighty said molecules, or comprising one hundred and ninety said molecules, or comprising two hundred said molecules, or comprising two hundred and twenty said molecules, or comprising two hundred and forty said molecules, or comprising two hundred and sixty said molecules, or comprising two hundred and eighty said molecules, or comprising three hundred said molecules, or comprising four hundred said molecules, or comprising five hundred said molecules, or comprising six hundred said molecules, or comprising seven hundred said molecules, or comprising eight hundred said molecules, or comprising nine hundred said molecules, or comprising one thousand said molecules.
69. A composition of any of claims 51 to 68, wherein each said molecule is linked to a solid phase support so as to be distinguishable from a mixture of other said molecules by hybridization to its complement.
70. The composition of claim 69, wherein each molecule is linked to a defined location on a said solid phase support, the defined location for each said molecule being different than the defined location for different other said molecules.
71. The composition of claim 70, wherein each said solid phase support is a microparticle and each said molecule is covalently to a different microparticle than each other different said molecule.
72. A composition according to any of claims 1 to 71, wherein each said molecule comprises a tag complement.
73. A composition according to any of claims 1 to 72, wherein any base is substituted by an analogue thereof.
74. A composition according to any of claims 1 to 73, wherein each said molecule comprises a tag complement.
75. A kit for sorting and identifying polynucleotides, the kit comprising one or more solid phase supports each having one or more spatially discrete regions, each such region having a uniform population of substantially identical tag complements covalently attached, and the tag complements each being selected from the set of oligonucleotides as defined in any of claims 1 to 84.
76. A kit according to claim 75, wherein there is a tag complement for each said oligonucleotide of a said composition.
77. A kit according to claim 75 or 76 wherein said one or more solid phase supports is a planar substrate and wherein said one or more spatially discrete regions is a plurality of spatially addressable regions.
78. A kit according to any of claims 75 to 77 wherein said one or more solid phase supports is a plurality of microparticles.
79. A kit according to claim 78 wherein said microparticles each have a diameter in the range of from 5 to 40 µm.
80. A kit according to claim 78 or 79, wherein each microparticle is spectrophotometrically unique from each other microparticle having a different oligonucleotide attached thereto.
81. A method of analyzing a biological sample comprising a biological sequence for the presence of a mutation or polymorphism at a locus of the nucleic acid, the method comprising:
(A) amplifying the nucleic acid molecule in the presence of a first primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements as defined in claim 74 to form an amplified molecule with a 5'-end with a sequence complementary to the sequence of the tag;
(B) extending the amplified molecule in the presence of a polymerase and a second primer having 5'-end complementary the 3'-end of the amplified sequence, with the 3'-end of the second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of incorporation during transciption by the polymerise onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization;
and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus of the amplified sequence;
(C) specifically hybridizing the second primer to a tag complement having the tag complement sequence of (A); and (D) detecting the nucleotide derivative incorporated into the second primer in (B) so as to identify the base located at the locus of the nucleic acid.
(A) amplifying the nucleic acid molecule in the presence of a first primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements as defined in claim 74 to form an amplified molecule with a 5'-end with a sequence complementary to the sequence of the tag;
(B) extending the amplified molecule in the presence of a polymerase and a second primer having 5'-end complementary the 3'-end of the amplified sequence, with the 3'-end of the second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of incorporation during transciption by the polymerise onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization;
and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus of the amplified sequence;
(C) specifically hybridizing the second primer to a tag complement having the tag complement sequence of (A); and (D) detecting the nucleotide derivative incorporated into the second primer in (B) so as to identify the base located at the locus of the nucleic acid.
82. A method of analyzing a biological sample comprising a plurality of nucleic acid molecules for the presence of a mutation or polymorphism at a locus of each nucleic acid molecule, for each nucleic acid molecule, the method comprising:
(A) amplifying the nucleic acid molecule in the presence of a first primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements as defined in claim 74 to form an amplified molecule with a 5'-end with a sequence complementary to the sequence of the tag;
(B) extending the amplified molecule in the presence of a polymerise and a second primer having 5'-end complementary the 3'-end of the amplified sequence, the 3'-end of the second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of incorporation during transciption by the polymerise onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization;
and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus of the amplified molecule;
(C) specifically hybridizing the second primer to a tag complement having the tag complement sequence of (A); and (D) detecting the nucleotide derivative incorporated into the, second primer in (B) so as to identify the base located at the locus of the nucleic acid;
wherein each tag of (A) is unique for each nucleic acid molecule and steps (A) and (B) are carried out with said nucleic molecules in the presence of each other.
(A) amplifying the nucleic acid molecule in the presence of a first primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements as defined in claim 74 to form an amplified molecule with a 5'-end with a sequence complementary to the sequence of the tag;
(B) extending the amplified molecule in the presence of a polymerise and a second primer having 5'-end complementary the 3'-end of the amplified sequence, the 3'-end of the second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of incorporation during transciption by the polymerise onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization;
and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus of the amplified molecule;
(C) specifically hybridizing the second primer to a tag complement having the tag complement sequence of (A); and (D) detecting the nucleotide derivative incorporated into the, second primer in (B) so as to identify the base located at the locus of the nucleic acid;
wherein each tag of (A) is unique for each nucleic acid molecule and steps (A) and (B) are carried out with said nucleic molecules in the presence of each other.
83. A method of analyzing a biological sample comprising a plurality of double stranded complementary nucleic acid molecules for the presence of a mutation or polymorphism at a locus of each nucleic acid molecule, for each nucleic acid molecule, the method comprising:
(A) amplifying the double stranded molecule in the presence of a pair of first primers, each primer having an identical 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements as defined in claim 74 to form amplified molecules with 5'-ends with a sequence complementary to the sequence of the tag;
(B) extending the amplified molecules in the presence of a polymerase and a pair of second primers each second primer having a 5'-end complementary a 3'-end of the amplified sequence, the 3'-end of each said second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate derivatives each of which is:
(i) capable of incorporation during transciption by the polymerase onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization; and (iii) capable of differential detection, one from the other;
(C) specifically hybridizing each of the second primers to a tag complement having the tag complement sequence of (A); and (D) detecting the nucleotide derivative incorporated into the second primers in (B) so as to identify the base located at said locus;
wherein the sequence of each tag of (A) is unique for each nucleic acid molecule and steps (A) and (B) are carried out with said nucleic molecules in the presence of each other.
(A) amplifying the double stranded molecule in the presence of a pair of first primers, each primer having an identical 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements as defined in claim 74 to form amplified molecules with 5'-ends with a sequence complementary to the sequence of the tag;
(B) extending the amplified molecules in the presence of a polymerase and a pair of second primers each second primer having a 5'-end complementary a 3'-end of the amplified sequence, the 3'-end of each said second primer extending to immediately adjacent said locus, in the presence of a plurality of nucleoside triphosphate derivatives each of which is:
(i) capable of incorporation during transciption by the polymerase onto the 3'-end of a growing nucleotide strand; (ii) causes termination of polymerization; and (iii) capable of differential detection, one from the other;
(C) specifically hybridizing each of the second primers to a tag complement having the tag complement sequence of (A); and (D) detecting the nucleotide derivative incorporated into the second primers in (B) so as to identify the base located at said locus;
wherein the sequence of each tag of (A) is unique for each nucleic acid molecule and steps (A) and (B) are carried out with said nucleic molecules in the presence of each other.
84. A method of analyzing a biological sample comprising a plurality of nucleic acid molecules for the presence of a mutation or polymorphism at a locus of each nucleic acid molecule, for each nucleic acid molecule, the method comprising:
(a) hybridizing the molecule and a primer, the primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements as defined in claim 74 and a 3'-end extending to immediately adjacent the locus;
(b) enzymatically extending the 3'-end of the primer in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of enzymatic incorporation onto the 3'-end of a growing nucleotide strand; (ii) causes termination of said extension; and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus;
(c) specifically hybridizing the extended primer formed in step (b) to a tag complement having the tag complement sequence of (a); and (d) detecting the nucleotide derivative incorporated into the primer in step (b) so as to identify the base located at the locus of the nucleic acid molecule;
wherein each tag of (a) is unique for each nucleic acid molecule and steps (a) and (b) are carried out with said nucleic molecules in the presence of each other.
(a) hybridizing the molecule and a primer, the primer having a 5'-sequence having the sequence of a tag complementary to the sequence of a tag complement belonging to a family of tag complements as defined in claim 74 and a 3'-end extending to immediately adjacent the locus;
(b) enzymatically extending the 3'-end of the primer in the presence of a plurality of nucleoside triphosphate derivatives each of which is: (i) capable of enzymatic incorporation onto the 3'-end of a growing nucleotide strand; (ii) causes termination of said extension; and (iii) capable of differential detection, one from the other, wherein there is a said derivative complementary to each possible nucleotide present at said locus;
(c) specifically hybridizing the extended primer formed in step (b) to a tag complement having the tag complement sequence of (a); and (d) detecting the nucleotide derivative incorporated into the primer in step (b) so as to identify the base located at the locus of the nucleic acid molecule;
wherein each tag of (a) is unique for each nucleic acid molecule and steps (a) and (b) are carried out with said nucleic molecules in the presence of each other.
85. The method of claim 82 wherein each said derivative is a dideoxy nucleoside triphosphate.
86. The method of claim 84, wherein each respective complement is attached as a uniform population of substantially identical complements in a spacially discrete region on one or more said solid phase supports.
87. The method of claim 86, each said tag complement comprises a label, each such label being different for respective complements, and step (d) includes detecting the presence of the different labels for respective hybridization complexes of bound tags and tag complements.
88. The hybridized molecule and primer of step (A) of any of claims 84 to 87.
89. A method of determining the presence of a target suspected of being contained in a mixture, the method comprising the steps of:
(i) labelling the target with a first label;
(ii) providing a first detection moiety capable of specific binding to the target and including a first tag;
(iii) exposing a sample of the mixture to the detection moiety under conditions suitable to permit (or cause) said specific binding of the molecule and target;
(iv) providing a family of tag complements as defined in claim 74 wherein the family contains a first tag complement having a sequence complementary to that of the first tag;
(v) exposing the sample to the family of tag complements under conditions suitable to permit (or cause) specific hybridization of the first tag and its tag complement;
(vi) determining whether a said first detection moiety hybridized to a first said tag complement is bound to a said labelled target in order to determine the presence or absence said target in the mixture.
(i) labelling the target with a first label;
(ii) providing a first detection moiety capable of specific binding to the target and including a first tag;
(iii) exposing a sample of the mixture to the detection moiety under conditions suitable to permit (or cause) said specific binding of the molecule and target;
(iv) providing a family of tag complements as defined in claim 74 wherein the family contains a first tag complement having a sequence complementary to that of the first tag;
(v) exposing the sample to the family of tag complements under conditions suitable to permit (or cause) specific hybridization of the first tag and its tag complement;
(vi) determining whether a said first detection moiety hybridized to a first said tag complement is bound to a said labelled target in order to determine the presence or absence said target in the mixture.
90. The method of claim 89 wherein said first tag complement is linked to a solid support at a specific location of the support and step (vi) includes detecting the presence the first label at said specified location.
91. The method of claim 89 wherein said first tag complement comprises a second label and step (vi) includes detecting the presence of the first and second labels in a hybridized complex of the moiety and the first tag complement.
92. The method of claim 89 wherein said target is selected from the group consisting of organic molecules, antigens, proteins, polypeptides, antibodies and nucleic acids.
93. The method of claim 92, wherein said target is an antigen and said first molecule is an antibody specific for said antigen.
94. The method of claim 93, wherein the antigen is a polypeptide or protein and the labelling step includes conjugation of fluorescent molecules, digoxigenin, biotinylation and the like.
95. The method of claim 94, wherein said target is a nucleic acid and the labelling step includes incorporation of fluorescent molecules, radiolabelled nucleotide, digoxigenin, biotinylation and the like.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26371001P | 2001-01-25 | 2001-01-25 | |
| US60/263,710 | 2001-01-25 | ||
| US30379901P | 2001-07-10 | 2001-07-10 | |
| US60/303,799 | 2001-07-10 | ||
| PCT/CA2002/000089 WO2002059355A2 (en) | 2001-01-25 | 2002-01-25 | Polynucleotides for use as tags and tag complements, manufacture and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2435551A1 true CA2435551A1 (en) | 2002-08-01 |
| CA2435551C CA2435551C (en) | 2011-10-25 |
Family
ID=26950006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2435551A Expired - Lifetime CA2435551C (en) | 2001-01-25 | 2002-01-25 | Families of non-cross-hybridizing polynucleotides for use as tags and tag complements, manufacture and use thereof |
| CA2435612A Expired - Lifetime CA2435612C (en) | 2001-01-25 | 2002-01-25 | Polynucleotides for use as tags and tag complements, manufacture and use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2435612A Expired - Lifetime CA2435612C (en) | 2001-01-25 | 2002-01-25 | Polynucleotides for use as tags and tag complements, manufacture and use thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7645868B2 (en) |
| EP (4) | EP2325336B1 (en) |
| JP (3) | JP4588976B2 (en) |
| AT (1) | ATE546545T1 (en) |
| AU (3) | AU2002227829C1 (en) |
| BR (2) | BRPI0206747B1 (en) |
| CA (2) | CA2435551C (en) |
| DK (1) | DK1364065T3 (en) |
| ES (1) | ES2382542T3 (en) |
| WO (2) | WO2002059354A2 (en) |
Families Citing this family (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0206747B1 (en) * | 2001-01-25 | 2017-03-21 | Luminex Molecular Diagnostics Inc | polynucleotides for use as labels and tag complements, manufacture and use thereof |
| US7226737B2 (en) * | 2001-01-25 | 2007-06-05 | Luminex Molecular Diagnostics, Inc. | Polynucleotides for use as tags and tag complements, manufacture and use thereof |
| US20110151438A9 (en) | 2001-11-19 | 2011-06-23 | Affymetrix, Inc. | Methods of Analysis of Methylation |
| US7208295B2 (en) | 2001-11-19 | 2007-04-24 | Affymetrix, Inc. | Multiplex oligonucleotide addition and target amplification |
| GB0308852D0 (en) * | 2003-04-16 | 2003-05-21 | Lingvitae As | Method |
| US7879543B2 (en) | 2003-11-17 | 2011-02-01 | Luminex Molecular Diagnostics, Inc. | Method of detecting mutations associated with thrombosis |
| EP1766062A4 (en) * | 2004-06-01 | 2008-07-09 | Tm Bioscience Corp | Method of detecting cystic fibrosis associated mutations |
| WO2006002525A1 (en) * | 2004-06-30 | 2006-01-12 | Tm Bioscience Pgx, Inc. | Method of detecting mutations in the gene encoding cytochrome p450-2c9 |
| DE602005021971D1 (en) * | 2004-06-30 | 2010-08-05 | Luminex Molecular Diagnostics | PROCEDURE FOR DETECTING MUTATIONS IN THE CYTOCHROM P450-2D6 CODING GEN |
| CA2575422A1 (en) * | 2004-07-30 | 2006-02-02 | Tm Bioscience Pgx, Inc. | Method of detecting mutations in the gene encoding cytochrome p450-2c19 |
| WO2007025594A1 (en) * | 2005-07-07 | 2007-03-08 | Pamgene Bv | Method for detection and quantification of target nucleic acids in a sample |
| US7807359B2 (en) * | 2006-12-01 | 2010-10-05 | Quest Diagnostics Investments Incorporated | Methods of detecting TPMT mutations |
| EP2857526B1 (en) | 2006-12-13 | 2016-08-17 | Luminex Corporation | Systems and methods for multiplex analysis of PCR in real time |
| WO2009059199A2 (en) * | 2007-11-02 | 2009-05-07 | Hunch Inc. | Interactive machine learning advice facility |
| EP2215245A2 (en) * | 2007-11-02 | 2010-08-11 | Luminex Molecular Diagnostics, Inc. | One-step target detection assay |
| US8008019B2 (en) * | 2007-11-28 | 2011-08-30 | Luminex Molecular Diagnostics | Use of dual-tags for the evaluation of genomic variable repeat regions |
| US8039794B2 (en) | 2008-12-16 | 2011-10-18 | Quest Diagnostics Investments Incorporated | Mass spectrometry assay for thiopurine-S-methyl transferase activity and products generated thereby |
| WO2010127186A1 (en) | 2009-04-30 | 2010-11-04 | Prognosys Biosciences, Inc. | Nucleic acid constructs and methods of use |
| EP2789689B1 (en) | 2009-06-29 | 2016-04-27 | Luminex Corporation | Chimeric primers with hairpin conformations and methods of using same |
| US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
| HUE026666T2 (en) | 2010-04-05 | 2016-07-28 | Prognosys Biosciences Inc | Spatially encoded biological assays |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| CN102010900B (en) * | 2010-06-08 | 2013-04-24 | 广州益善生物技术有限公司 | Liquid chip and specific primer for detecting SNP of GPIIIa gene and liquid chip and specific primer for detecting SNP of GPIIIa and COX-1 genes |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| CN103748236B (en) | 2011-04-15 | 2018-12-25 | 约翰·霍普金斯大学 | Safe sequencing system |
| WO2013049613A1 (en) | 2011-09-29 | 2013-04-04 | Luminex Corporation | Hydrolysis probes |
| GB2513024B (en) | 2012-02-27 | 2016-08-31 | Cellular Res Inc | A clonal amplification method |
| CN103374601A (en) * | 2012-04-11 | 2013-10-30 | 广州益善生物技术有限公司 | Specific primers and liquid-phase chip for chromosome 5p15 region SNP detection |
| CN103374598A (en) * | 2012-04-11 | 2013-10-30 | 广州益善生物技术有限公司 | Specific primers and liquid-phase chip for HLA-A gene mutation detection |
| CN103374606B (en) * | 2012-04-12 | 2015-04-22 | 益善生物技术股份有限公司 | CHEK1 (checkpoint kinase 1) gene mutation detection specific primers and liquid chip |
| CN103374610A (en) * | 2012-04-12 | 2013-10-30 | 广州益善生物技术有限公司 | CHRNA3 (cholinergic receptor, nicotinic, alpha 3) gene mutation detection specific primers and liquid chip |
| CN103374605A (en) * | 2012-04-12 | 2013-10-30 | 广州益善生物技术有限公司 | ATR (ataxia telangiectasia-mutated and Rad3-related) gene mutation detection specific primers and liquid chip |
| CN103451272A (en) * | 2012-05-31 | 2013-12-18 | 益善生物技术股份有限公司 | BAT3 gene mutation detection specific primer and liquid phase chip |
| CN103451274A (en) * | 2012-05-31 | 2013-12-18 | 益善生物技术股份有限公司 | CHRNA5 gene mutation detection specific primer and liquid phase chip |
| US9663818B2 (en) | 2012-06-15 | 2017-05-30 | The University Of Chicago | Oligonucleotide-mediated quantitative multiplexed immunoassays |
| CN103571917A (en) * | 2012-07-18 | 2014-02-12 | 益善生物技术股份有限公司 | Specific detection primers and detection liquid phase chip for ADH1B gene mutation |
| CN103571918A (en) * | 2012-07-18 | 2014-02-12 | 益善生物技术股份有限公司 | Specific detection primers and detection liquid phase chip for FYCO1 gene mutation |
| CN103571931A (en) * | 2012-07-18 | 2014-02-12 | 益善生物技术股份有限公司 | Specific primers and liquid chip for EHBP1 (EH domain binding protein 1) gene mutation detection |
| AU2013338393B2 (en) | 2012-10-29 | 2017-05-11 | The Johns Hopkins University | Papanicolaou test for ovarian and endometrial cancers |
| CN103849938B (en) * | 2012-12-04 | 2016-08-03 | 益善生物技术股份有限公司 | MAP3K1 detection in Gene Mutation specific primer and liquid-phase chip |
| CN103849943B (en) * | 2012-12-04 | 2016-08-03 | 益善生物技术股份有限公司 | MC1R detection in Gene Mutation specific primer and liquid-phase chip |
| CN103849941B (en) * | 2012-12-04 | 2016-06-01 | 益善生物技术股份有限公司 | TYR detection in Gene Mutation Auele Specific Primer and liquid-phase chip |
| CN103849939B (en) * | 2012-12-04 | 2016-06-22 | 益善生物技术股份有限公司 | RAD51L1 detection in Gene Mutation specific primer and liquid-phase chip |
| CN103849942B (en) * | 2012-12-04 | 2016-07-13 | 益善生物技术股份有限公司 | TOX3 detection in Gene Mutation specific primer and liquid-phase chip |
| CN103849940B (en) * | 2012-12-04 | 2016-09-14 | 益善生物技术股份有限公司 | BARD1 detection in Gene Mutation specific primer and liquid-phase chip |
| EP3521452B1 (en) | 2013-06-19 | 2021-08-04 | Luminex Corporation | Real-time multiplexed hydrolysis probe assay |
| CA2916660C (en) | 2013-06-25 | 2022-05-17 | Prognosys Biosciences, Inc. | Spatially encoded biological assays using a microfluidic device |
| KR102129506B1 (en) | 2013-08-09 | 2020-07-06 | 루미넥스 코포레이션 | Probes for improved melt discrimination and multiplexing in nucleic acid assays |
| ES2857908T3 (en) | 2013-08-28 | 2021-09-29 | Becton Dickinson Co | Massively parallel single cell analysis |
| EP3055676A1 (en) | 2013-10-07 | 2016-08-17 | Cellular Research, Inc. | Methods and systems for digitally counting features on arrays |
| MX2014003938A (en) * | 2014-04-01 | 2015-09-30 | Univ Nac Autónoma De México | Microarray for the detection of enteropathogenic microorganisms in environmental and biological samples. |
| CN105316398A (en) * | 2014-07-30 | 2016-02-10 | 益善生物技术股份有限公司 | Amplification primer for detecting food-borne pathogenic microorganisms and liquid chip kit |
| CN113637728A (en) | 2014-08-11 | 2021-11-12 | 卢米耐克斯公司 | Probes for improved melt resolution and multiplexing in nucleic acid assays |
| EP3259371B1 (en) | 2015-02-19 | 2020-09-02 | Becton, Dickinson and Company | High-throughput single-cell analysis combining proteomic and genomic information |
| CN107208158B (en) | 2015-02-27 | 2022-01-28 | 贝克顿迪金森公司 | Spatially addressable molecular barcode |
| ES2934982T3 (en) | 2015-03-30 | 2023-02-28 | Becton Dickinson Co | Methods for encoding with combinatorial barcodes |
| US10774374B2 (en) | 2015-04-10 | 2020-09-15 | Spatial Transcriptomics AB and Illumina, Inc. | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| CN107580632B (en) | 2015-04-23 | 2021-12-28 | 贝克顿迪金森公司 | Methods and compositions for whole transcriptome amplification |
| WO2016196229A1 (en) | 2015-06-01 | 2016-12-08 | Cellular Research, Inc. | Methods for rna quantification |
| EP3708677A1 (en) | 2015-07-17 | 2020-09-16 | Luminex Corporation | Methods and compositions for catalytic dna assays |
| US11286531B2 (en) | 2015-08-11 | 2022-03-29 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| CN108026524A (en) | 2015-09-11 | 2018-05-11 | 赛卢拉研究公司 | Method and composition for nucleic acid library standardization |
| ES2956757T3 (en) * | 2016-05-02 | 2023-12-27 | Becton Dickinson Co | Accurate molecular barcode coding |
| US10301677B2 (en) | 2016-05-25 | 2019-05-28 | Cellular Research, Inc. | Normalization of nucleic acid libraries |
| EP3465502B1 (en) | 2016-05-26 | 2024-04-10 | Becton, Dickinson and Company | Molecular label counting adjustment methods |
| US10202641B2 (en) | 2016-05-31 | 2019-02-12 | Cellular Research, Inc. | Error correction in amplification of samples |
| US10640763B2 (en) | 2016-05-31 | 2020-05-05 | Cellular Research, Inc. | Molecular indexing of internal sequences |
| EP3516400B1 (en) | 2016-09-26 | 2023-08-16 | Becton, Dickinson and Company | Measurement of protein expression using reagents with barcoded oligonucleotide sequences |
| WO2018132610A1 (en) | 2017-01-13 | 2018-07-19 | Cellular Research, Inc. | Hydrophilic coating of fluidic channels |
| CN110382708A (en) | 2017-02-01 | 2019-10-25 | 赛卢拉研究公司 | Selective amplification is carried out using blocking property oligonucleotides |
| CA3059559A1 (en) | 2017-06-05 | 2018-12-13 | Becton, Dickinson And Company | Sample indexing for single cells |
| WO2019126209A1 (en) | 2017-12-19 | 2019-06-27 | Cellular Research, Inc. | Particles associated with oligonucleotides |
| US11773441B2 (en) | 2018-05-03 | 2023-10-03 | Becton, Dickinson And Company | High throughput multiomics sample analysis |
| EP3788170A1 (en) | 2018-05-03 | 2021-03-10 | Becton, Dickinson and Company | Molecular barcoding on opposite transcript ends |
| US11519033B2 (en) | 2018-08-28 | 2022-12-06 | 10X Genomics, Inc. | Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample |
| WO2020072380A1 (en) | 2018-10-01 | 2020-04-09 | Cellular Research, Inc. | Determining 5' transcript sequences |
| JP2022506546A (en) | 2018-11-08 | 2022-01-17 | ベクトン・ディキンソン・アンド・カンパニー | Single-cell whole transcriptome analysis using random priming |
| EP3894552A1 (en) | 2018-12-13 | 2021-10-20 | Becton, Dickinson and Company | Selective extension in single cell whole transcriptome analysis |
| US11649485B2 (en) | 2019-01-06 | 2023-05-16 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
| US11926867B2 (en) | 2019-01-06 | 2024-03-12 | 10X Genomics, Inc. | Generating capture probes for spatial analysis |
| WO2020150356A1 (en) | 2019-01-16 | 2020-07-23 | Becton, Dickinson And Company | Polymerase chain reaction normalization through primer titration |
| ES2945227T3 (en) | 2019-01-23 | 2023-06-29 | Becton Dickinson Co | Antibody Associated Oligonucleotides |
| WO2021016239A1 (en) | 2019-07-22 | 2021-01-28 | Becton, Dickinson And Company | Single cell chromatin immunoprecipitation sequencing assay |
| EP4055185A1 (en) | 2019-11-08 | 2022-09-14 | 10X Genomics, Inc. | Spatially-tagged analyte capture agents for analyte multiplexing |
| WO2021092433A2 (en) | 2019-11-08 | 2021-05-14 | 10X Genomics, Inc. | Enhancing specificity of analyte binding |
| JP2023500679A (en) | 2019-11-08 | 2023-01-10 | ベクトン・ディキンソン・アンド・カンパニー | Using random priming to obtain full-length V(D)J information for immune repertoire sequencing |
| DK3891300T3 (en) | 2019-12-23 | 2023-05-22 | 10X Genomics Inc | METHODS FOR SPATIAL ANALYSIS USING RNA TEMPLATE LIGATION |
| CN115244184A (en) | 2020-01-13 | 2022-10-25 | 贝克顿迪金森公司 | Methods and compositions for quantifying protein and RNA |
| US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
| US11702693B2 (en) | 2020-01-21 | 2023-07-18 | 10X Genomics, Inc. | Methods for printing cells and generating arrays of barcoded cells |
| US11821035B1 (en) | 2020-01-29 | 2023-11-21 | 10X Genomics, Inc. | Compositions and methods of making gene expression libraries |
| US11898205B2 (en) | 2020-02-03 | 2024-02-13 | 10X Genomics, Inc. | Increasing capture efficiency of spatial assays |
| US11732300B2 (en) | 2020-02-05 | 2023-08-22 | 10X Genomics, Inc. | Increasing efficiency of spatial analysis in a biological sample |
| US11835462B2 (en) | 2020-02-11 | 2023-12-05 | 10X Genomics, Inc. | Methods and compositions for partitioning a biological sample |
| US11891654B2 (en) | 2020-02-24 | 2024-02-06 | 10X Genomics, Inc. | Methods of making gene expression libraries |
| US11926863B1 (en) | 2020-02-27 | 2024-03-12 | 10X Genomics, Inc. | Solid state single cell method for analyzing fixed biological cells |
| US11768175B1 (en) | 2020-03-04 | 2023-09-26 | 10X Genomics, Inc. | Electrophoretic methods for spatial analysis |
| CN115916999A (en) | 2020-04-22 | 2023-04-04 | 10X基因组学有限公司 | Methods for spatial analysis using targeted RNA depletion |
| EP4150118A1 (en) | 2020-05-14 | 2023-03-22 | Becton Dickinson and Company | Primers for immune repertoire profiling |
| EP4153775A1 (en) | 2020-05-22 | 2023-03-29 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
| AU2021275906A1 (en) | 2020-05-22 | 2022-12-22 | 10X Genomics, Inc. | Spatial analysis to detect sequence variants |
| WO2021242834A1 (en) | 2020-05-26 | 2021-12-02 | 10X Genomics, Inc. | Method for resetting an array |
| AU2021283184A1 (en) | 2020-06-02 | 2023-01-05 | 10X Genomics, Inc. | Spatial transcriptomics for antigen-receptors |
| AU2021283174A1 (en) | 2020-06-02 | 2023-01-05 | 10X Genomics, Inc. | Nucleic acid library methods |
| WO2021252499A1 (en) | 2020-06-08 | 2021-12-16 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
| EP4165207A1 (en) | 2020-06-10 | 2023-04-19 | 10X Genomics, Inc. | Methods for determining a location of an analyte in a biological sample |
| AU2021294334A1 (en) | 2020-06-25 | 2023-02-02 | 10X Genomics, Inc. | Spatial analysis of DNA methylation |
| US11761038B1 (en) | 2020-07-06 | 2023-09-19 | 10X Genomics, Inc. | Methods for identifying a location of an RNA in a biological sample |
| US11932901B2 (en) | 2020-07-13 | 2024-03-19 | Becton, Dickinson And Company | Target enrichment using nucleic acid probes for scRNAseq |
| US11926822B1 (en) | 2020-09-23 | 2024-03-12 | 10X Genomics, Inc. | Three-dimensional spatial analysis |
| US11827935B1 (en) | 2020-11-19 | 2023-11-28 | 10X Genomics, Inc. | Methods for spatial analysis using rolling circle amplification and detection probes |
| WO2022109343A1 (en) | 2020-11-20 | 2022-05-27 | Becton, Dickinson And Company | Profiling of highly expressed and lowly expressed proteins |
| EP4121555A1 (en) | 2020-12-21 | 2023-01-25 | 10X Genomics, Inc. | Methods, compositions, and systems for capturing probes and/or barcodes |
| CN112553379B (en) * | 2020-12-30 | 2022-08-19 | 湖北新纵科病毒疾病工程技术有限公司 | Method and kit for detecting respiratory infectious disease virus based on liquid chip |
| WO2022198068A1 (en) | 2021-03-18 | 2022-09-22 | 10X Genomics, Inc. | Multiplex capture of gene and protein expression from a biological sample |
| EP4196605A1 (en) | 2021-09-01 | 2023-06-21 | 10X Genomics, Inc. | Methods, compositions, and kits for blocking a capture probe on a spatial array |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851331A (en) | 1986-05-16 | 1989-07-25 | Allied Corporation | Method and kit for polynucleotide assay including primer-dependant DNA polymerase |
| US5149625A (en) | 1987-08-11 | 1992-09-22 | President And Fellows Of Harvard College | Multiplex analysis of DNA |
| US4942124A (en) | 1987-08-11 | 1990-07-17 | President And Fellows Of Harvard College | Multiplex sequencing |
| US5002867A (en) | 1988-04-25 | 1991-03-26 | Macevicz Stephen C | Nucleic acid sequence determination by multiple mixed oligonucleotide probes |
| AU5640090A (en) | 1989-03-21 | 1990-11-05 | Collaborative Research Inc. | A dna diagnostic test using an exonuclease activity |
| US6040138A (en) * | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
| EP0675966B1 (en) | 1992-02-19 | 2004-10-06 | The Public Health Research Institute Of The City Of New York, Inc. | Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids |
| US5981176A (en) | 1992-06-17 | 1999-11-09 | City Of Hope | Method of detecting and discriminating between nucleic acid sequences |
| WO1994027150A1 (en) * | 1993-05-10 | 1994-11-24 | Nissui Pharmaceutical Co., Ltd. | Method for assaying more than one immunological ligand, and assay reagent and kit therefor |
| US5695934A (en) | 1994-10-13 | 1997-12-09 | Lynx Therapeutics, Inc. | Massively parallel sequencing of sorted polynucleotides |
| US6013445A (en) | 1996-06-06 | 2000-01-11 | Lynx Therapeutics, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
| US5604097A (en) | 1994-10-13 | 1997-02-18 | Spectragen, Inc. | Methods for sorting polynucleotides using oligonucleotide tags |
| US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
| GB9507238D0 (en) | 1995-04-07 | 1995-05-31 | Isis Innovation | Detecting dna sequence variations |
| AU718357B2 (en) * | 1995-06-07 | 2000-04-13 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
| US5830539A (en) * | 1995-11-17 | 1998-11-03 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Methods for functionalizing and coating substrates and devices made according to the methods |
| EP1958955B1 (en) | 1996-02-09 | 2013-09-04 | Cornell Research Foundation, Inc. | Spatially addressable oligonucleotide arrays and method of making the same |
| US6458530B1 (en) * | 1996-04-04 | 2002-10-01 | Affymetrix Inc. | Selecting tag nucleic acids |
| GB9609441D0 (en) * | 1996-05-04 | 1996-07-10 | Zeneca Ltd | Process |
| TW349909B (en) | 1997-01-22 | 1999-01-11 | Alps Electric Co Ltd | Hot transfer printer |
| US6205444B1 (en) | 1997-10-17 | 2001-03-20 | International Business Machines Corporation | Multiple sequence alignment system and method |
| US6238869B1 (en) * | 1997-12-19 | 2001-05-29 | High Throughput Genomics, Inc. | High throughput assay system |
| US6395481B1 (en) * | 1999-02-16 | 2002-05-28 | Arch Development Corp. | Methods for detection of promoter polymorphism in a UGT gene promoter |
| CA2366459A1 (en) * | 1999-03-26 | 2000-10-05 | Affymetrix, Inc. | Universal arrays |
| US6355431B1 (en) | 1999-04-20 | 2002-03-12 | Illumina, Inc. | Detection of nucleic acid amplification reactions using bead arrays |
| US6287778B1 (en) | 1999-10-19 | 2001-09-11 | Affymetrix, Inc. | Allele detection using primer extension with sequence-coded identity tags |
| CA2397658A1 (en) | 2000-02-10 | 2001-08-16 | Tm Bioscience Corporation | Method of designing and selecting polynucleotide sequences |
| US7157564B1 (en) | 2000-04-06 | 2007-01-02 | Affymetrix, Inc. | Tag nucleic acids and probe arrays |
| WO2001098327A2 (en) * | 2000-06-22 | 2001-12-27 | Theravance, Inc. | Glycopeptide carboxy-saccharide derivatives |
| US20030180953A1 (en) * | 2000-12-29 | 2003-09-25 | Elitra Pharmaceuticals, Inc. | Gene disruption methodologies for drug target discovery |
| BRPI0206747B1 (en) | 2001-01-25 | 2017-03-21 | Luminex Molecular Diagnostics Inc | polynucleotides for use as labels and tag complements, manufacture and use thereof |
| US7226737B2 (en) | 2001-01-25 | 2007-06-05 | Luminex Molecular Diagnostics, Inc. | Polynucleotides for use as tags and tag complements, manufacture and use thereof |
-
2002
- 2002-01-25 BR BRPI0206747A patent/BRPI0206747B1/en active IP Right Grant
- 2002-01-25 US US10/470,073 patent/US7645868B2/en active Active
- 2002-01-25 JP JP2002559836A patent/JP4588976B2/en not_active Expired - Fee Related
- 2002-01-25 CA CA2435551A patent/CA2435551C/en not_active Expired - Lifetime
- 2002-01-25 EP EP10012192.0A patent/EP2325336B1/en not_active Expired - Lifetime
- 2002-01-25 DK DK02709941.5T patent/DK1364065T3/en active
- 2002-01-25 WO PCT/CA2002/000087 patent/WO2002059354A2/en active IP Right Grant
- 2002-01-25 AU AU2002227829A patent/AU2002227829C1/en not_active Expired
- 2002-01-25 ES ES02709941T patent/ES2382542T3/en not_active Expired - Lifetime
- 2002-01-25 AT AT02709941T patent/ATE546545T1/en active
- 2002-01-25 CA CA2435612A patent/CA2435612C/en not_active Expired - Lifetime
- 2002-01-25 EP EP02709941A patent/EP1364065B1/en not_active Expired - Lifetime
- 2002-01-25 EP EP10012193A patent/EP2327794A3/en not_active Withdrawn
- 2002-01-25 WO PCT/CA2002/000089 patent/WO2002059355A2/en active Application Filing
- 2002-01-25 AU AU2002229435A patent/AU2002229435B2/en not_active Expired
- 2002-01-25 JP JP2002559837A patent/JP4422963B2/en not_active Expired - Fee Related
- 2002-01-25 BR BRPI0206746A patent/BRPI0206746B8/en not_active IP Right Cessation
- 2002-01-25 EP EP02710715A patent/EP1356117A2/en not_active Withdrawn
-
2008
- 2008-03-20 AU AU2008201349A patent/AU2008201349B2/en not_active Expired
-
2009
- 2009-08-19 JP JP2009190457A patent/JP5189569B2/en not_active Expired - Lifetime
- 2009-12-21 US US12/643,570 patent/US8624014B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2435551A1 (en) | Families of non-cross-hybridizing polynucleotides for use as tags and tag complements, manufacture and use thereof | |
| JP6959378B2 (en) | Enzyme-free and amplification-free sequencing | |
| AU2017200433B2 (en) | Multivariate diagnostic assays and methods for using same | |
| US6821724B1 (en) | Methods of genetic analysis using nucleic acid arrays | |
| JP2004526433A5 (en) | ||
| US6238866B1 (en) | Detector for nucleic acid typing and methods of using the same | |
| JP2701092B2 (en) | Probe methods and compositions for detecting different DNA sequences | |
| US6214187B1 (en) | Denaturing gradient affinity electrophoresis and methods of use thereof | |
| US7144699B2 (en) | Iterative resequencing | |
| AU4965499A (en) | Method of using an improved peptide nucleic acid universal library to optimize dna sequence hybridation | |
| WO1998026098B1 (en) | Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom | |
| RU96103646A (en) | REAGENT-MARKER AND METHOD FOR CARRYING OUT ANALYSIS | |
| NZ334426A (en) | Characterising cDNA comprising cutting sample cDNAs with a first endonuclease, sorting fragments according to the un-paired ends of the DNA, cutting with a second endonuclease then sorting the fragments | |
| US20030190663A1 (en) | Novel assay for nucleic acid analysis | |
| EP2079850A2 (en) | Detection of chromosomal inversions | |
| US6312904B1 (en) | Characterizing nucleic acid | |
| EP1537238B1 (en) | Method for quantitative determination of polynucleotides in a mixture | |
| US20030198983A1 (en) | Methods of genetic analysis of human genes | |
| CN1091831A (en) | Detect the method for nucleic acid | |
| US20030082596A1 (en) | Methods of genetic analysis of probes: test3 | |
| JP2003505036A (en) | Multiple strand displacement for nucleic acid determination | |
| JP2002209584A (en) | Method for detecting nucleotide polymorphism | |
| US20130237450A1 (en) | Method for Detecting Nucleic Acids | |
| CA2392673A1 (en) | Comparative genomic hybridization (cgh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220125 |